CC-chemokine receptor five gene polymorphism in primary IgA nephropathy: The 32 bp deletion allele is associated with late progression to end-stage renal failure with dialysis

Kidney International

Volumn 69, Issue 3, 2006, Pages 565-572

  Berthoux, F C ^a,b,c   Berthoux, P ^a,b   Mariat, C ^a,b   Thibaudin, L ^a,b   Afiani, A ^a   Linossier, M T ^b  

^a University North Hospital   (France)

^b UNIVERSITÉ JEAN MONNET   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Chemokine receptor five (CCR5); Disease initiation; Disease progression; Gene polymorphism; IgA nephropathy; Prognostic markers

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADULT; ANALYTICAL ERROR; ARTICLE; BASE PAIRING; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENE FREQUENCY; GENOTYPE; HEMODIALYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KAPLAN MEIER METHOD; KIDNEY FAILURE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE;

ADULT; CASE-CONTROL STUDIES; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENOTYPE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, CCR5; REGRESSION ANALYSIS; RENAL DIALYSIS; SEQUENCE DELETION; SURVIVAL ANALYSIS;

EID: 31544442195     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000106     Document Type: Article

References (37)

1. Luster AD. Chemokine-chemotactic cytokines that mediate inflammation. New Engl J Med 1998; 338: 436-445.
2. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127.
3. Raport CJ, Gosling J, Schweickart VL et al. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1 beta and MIP-1 alpha. J Biol Chem 1996; 271: 17161-17166.
4. Combadière C, Ahuja SK, Tiffany HL, Murphy PM. Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1a, MIP-1b and RANTES. J Leucocyte Biol 1996; 60: 147-152.
5. Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC CKR-5. Nature 1996; 381: 667-673.
6. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
7. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273: 1856-1862.
8. Huang Y, Paxton WA, Wolinsky SM et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-1243.
9. Segerer S, Nelson PJ, Schlöndorff D. Chemokine, chemokine receptors, and renal disease. J Am Soc Nephrol 2000; 11: 152-176.
10. Anders HJ, Vielhauer V, Schlöndorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003; 63: 401-415.
11. Segerer S, Mack M, Regele H et al. Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int 1999; 56: 52-64.
12. Segerer S, Cui Y, Eitner F et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001; 37: 518-531.
13. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002; 347: 738-748.
14. Aguilar F, Nunez-Roldan A, Torres B et al. Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1770-1774.
15. Garred P, Madsen HO, Peterson J et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25: 1462-1465.
16. Mettimano M, Specchia ML, Ianni A et al. CCR5 and CCR2 gene polymorphism in hypertensive patients. Br J Biomed Sci 2003; 60: 19-21.
17. Sandford AJ, Zhu S, Bai TR et al. The role of the C-C chemokine receptor-5 Delta 32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and excreted. J Allergy Clin Immunol 2001; 108: 69-73.
18. Haase CG, Schmidt S, Faustmann PM. Frequencies of the G-protein beta2 subunit C825T polymorphism and the delta 32 mutation of the chemokine receptor-5 in patients with multiple sclerosis. Neurosci Lett 2002; 330: 293-295.
19. Zhao X, Gharizadeh B, Hjelmstrom P et al. Genotype of CCR2 and CCR5 chemokine receptors in human myasthenia gravis. Int J Mol Med 2003; 12: 749-753.
20. Pokarny V, McQueen F, Yeoman S et al. Evidence for negative association of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 487-490.
21. Fischereder M, Luckow B, Hocher B et al. CC-chemokine receptor 5 and renal transplant survival. Lancet 2001; 357: 1758-1761.
22. Panzer U, Schneider A, Steinmetz OM et al. The chemokine receptor 5Δ32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int 2005; 67: 75-81.
23. Anders HJ, Frink M, Linde Y et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003; 170: 5658-5666.
24. Schecter AD, Calderon TM, Berman AB et al. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000; 275: 5466-5471.
25. Gonzales P, Alvarez R, Batalla A et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001; 2: 191-195.
26. Tuglular S, Berthoux P, Berthoux F. Polymorphisms of the tumour necrosis factor α gene at position -308 and TNFd microsatellite in primary IgA nephropathy. Nephrol Dial Transplant 2003; 18: 724-731.
27. Thibaudin L, Berthoux P, Thibaudin D et al. G protein β3 subunit C825T polymorphism in primary IgA nephropathy. Kidney Int 2004; 66: 322-328.
28. Schena P, D'Altri C, Cerullo G et al. ACE gene polymorphism and IgA nephropathy: an ethnically homogeneous study and a metaanalysis. Kidney Int 2001; 60: 732-740.
29. Hsu SI, Ramirez SB, Winn MP et al. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int 2000; 57: 1818-1835.
30. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-loannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361: 567-571.
31. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003; 361: 598-604.
32. Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361: 865-872.
33. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic renal disease: evaluation, classification and stratification. Am J Kidney Dis 2000; 39(Suppl 1): S46-S75.
34. Alamartine E, Sabatier JC, Berthoux F. Comparison of pathological lesions on repeated renal biopsies in 73 patients with primary IgA glomerulo-nephritis: value of quantitative scoring and approach to final prognosis. Clin Nephrol 1990; 34: 45-51.
35. Alamartine E, Sabatier JC, Guérin C et al. Pronostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate. Am J Kidney Dis 1991; 18: 12-19.
36. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-202.
37. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720-727.